
    
      Primary Objective:

        -  Assess the efficacy of N91115 at 12 weeks when added to preexisting treatment with
           lumacaftor/ivacaftor in adult patients with CF who are homozygous for the F508del-CFTR
           mutation

      Secondary Objectives:

        -  Assess the effect of N91115 added to lumacaftor/ivacaftor on safety

        -  Assess the effect of lumacaftor/ivacaftor added to N91115 on the pharmacokinetics of
           N91115, lumacaftor, and ivacaftor
    
  